Full-Time

Global Category Director Sales & Distributor Services & Marketing Operations

SDS-MOPS, MedTech

Deadline 9/13/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

New Brunswick, NJ, USA

Hybrid

Hybrid work is required; approximately 5% domestic and international travel.

Bachelor's

Category
Operations & Logistics (1)
Required Skills
LLM
Sales
Financial analysis
Risk Management
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A bachelor's degree or equivalent is required.
  • A minimum of 10 years of progressive procurement, category management, or commercial leadership experience is required.
  • Demonstrated success leading regional or global category strategies is required.
  • A proven track record managing complex supplier ecosystems and strategic sourcing initiatives is required.
  • Experience influencing senior executive stakeholders across multiple functions and geographies is required.
  • Experience leading transformation, change management, and organizational improvement initiatives is required.
  • Required skills include category management strategy, leadership, supplier collaboration, team management, and vendor selection.
  • The successful candidate must demonstrate executive influence, category strategy, commercial negotiation, supplier ecosystem leadership, transformation delivery, financial and analytical acumen, and cross-functional leadership.
Responsibilities
  • Act as the senior procurement partner to MedTech commercial leadership teams.
  • Translate commercial growth priorities into procurement strategies supporting market expansion, distributor effectiveness, customer engagement, and commercial excellence.
  • Provide strategic procurement guidance to regional and country leadership teams.
  • Shape procurement priorities that enable sustainable competitive advantage and support business transformation initiatives.
  • Build relationships with stakeholders across commercial, finance, marketing, and regional leadership organizations.
  • Lead development and execution of SDS-MOPS category strategies.
  • Identify emerging industry trends and market dynamics for incorporation into procurement strategies.
  • Drive supplier segmentation, category governance, demand management, sustainability, and digital and artificial intelligence optimization.
  • Align regional business needs with global procurement priorities.
  • Establish category roadmaps balancing cost optimization, innovation, risk management, and supplier performance.
  • Lead strategic supplier relationship management for key segmented suppliers.
  • Develop and maintain long-term supplier partnerships supporting business growth and innovation.
  • Conduct complex commercial negotiations and provide sourcing recommendations for executive approval.
  • Drive global and regional cross-market sourcing initiatives, guiding request for information, request for quotation, and request for proposal programs.
  • Ensure supplier ecosystems remain competitive, resilient, and aligned with business objectives.
  • Deliver measurable procurement value through strategic sourcing, supplier performance improvement, and commercial innovation.
  • Establish performance metrics linking procurement outcomes to business objectives.
  • Own and drive achievement of procurement savings, productivity, and value-creation targets.
  • Shape annual and multi-year value-delivery roadmaps.
  • Own delivery of procurement value through structural cost reduction, demand management, and reinvestment for growth.
  • Foster collaboration across global, regional, and local procurement organizations.
  • Lead knowledge sharing and development of category expertise across regional procurement teams.
  • Coordinate with Global Category Leaders, Regional Procurement Leads, and business stakeholders to ensure strategy alignment and execution across categories.
  • Influence senior stakeholders and drive alignment across complex organizational structures.
  • Leverage market intelligence, supplier innovation, and emerging technologies to improve business outcomes.
  • Embed digital capabilities, analytics, automation, and artificial intelligence into procurement strategies and supplier solutions.
  • Identify opportunities to simplify processes and improve procurement effectiveness.
  • Drive continuous improvement initiatives enhancing speed, quality, simplification, and decision-making.
  • Position Procurement as a strategic enabler of MedTech commercial transformation.
  • Drive adoption of new operating models through change management and stakeholder engagement.
  • Influence stakeholders to adopt new operating models, sourcing approaches, and supplier strategies.
  • Build organizational capability through coaching, mentoring, and knowledge sharing.
  • Foster a culture of continuous improvement, innovation, and accountability.
  • Ensure Procurement remains responsive to changing business needs and external market conditions.
  • Own direct leadership responsibility for people management.
Desired Qualifications
  • An MBA or advanced degree is preferred.
  • Understanding of artificial intelligence concepts and frameworks, including responsible and ethical artificial intelligence practices, is preferred.
  • Experience generating effective prompts to boost efficiency and productivity is preferred.
  • Preferred skills include business data analysis, business savvy, compliance management, contract management, cost-benefit analysis, critical thinking, developing others, inclusive leadership, market savvy, negotiation, new program development, performance measurement, procurement policies, relationship building, risk management, spend analysis, strategic thinking, succession planning, and sustainable procurement.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.